Background--Low 25-hydroxyvitamin D levels are associated with an increased risk of cardiovascular events, but the effect of vitamin D supplementation on markers of vascular function associated with major adverse cardiovascular events is unclear.
L ow circulating levels of 25-hydroxyvitamin D (25(OH)D)
have been associated with a wide range of illness states and physiological derangements. Within the field of cardiometabolic medicine, low 25(OH)D levels have been associated with higher levels of blood pressure (BP), with diabetes mellitus, stroke, myocardial infarction, and heart failure 1,2 in observational studies. Vitamin D affects hundreds of gene targets and has effects on a wide variety of cell types and organ systems, including the heart and vascular system. 3, 4 Several pathophysiological pathways have been postulated to explain the observed associations between low 25(OH)D levels and cardiovascular disease, including effects on arterial stiffness, endothelial function, cytokine secretion, vascular endothelial growth factor, and cellular calcium influx. 4 Despite a sound rationale for improved cardiovascular health with vitamin D supplementation, results from intervention trials have been less encouraging. A recent individual participant data (IPD) meta-analysis reported that vitamin D supplementation had no significant effect on BP, 5 even in those participants with low baseline 25(OH)D levels or with high baseline BP. Similarly, only marginal effects were observed on glycemic control in a meta-analysis of vitamin D supplementation in participants with diabetes mellitus. 6 Meta-analyses of cardiovascular outcomes show no effect of vitamin D supplementation on myocardial infarction or stroke, but suggest a possible effect in reducing new diagnoses of heart failure. 7 It is important to note that these metaanalyses include mostly trials performed in participants at risk for falls or with osteoporosis and may therefore not be generalizable. Several large trials of vitamin D supplementation with adequate power to detect reductions in cardiovascular events are due to report over the next few years, but the first of these trials did not report any reduction in cardiovascular event rates in a population of older people in New Zealand. 8 These results call into question the causal link between vitamin D status and vascular health. Results from trials investigating the effect of vitamin D supplementation on aspects of vascular health other than BP have shown mixed results. Arterial stiffness and endothelial function measures are validated markers of cardiovascular disease risk and major adverse cardiac events, but the beneficial impact of vitamin D supplementation on these markers is unclear. We therefore performed a systematic review with meta-analysis of trial-level and individual participant-level data to ascertain whether (1) vitamin D supplementation improves measures of arterial stiffness and endothelial function and (2) certain subgroups of individuals are more likely to benefit.
Methods Data Sharing Statement
To preserve the rights of data owners, and as agreed with those who contributed data sets for this analysis, the data, analytical methods, and study materials will not be made available to other researchers for the purposes of reproducing the results or replicating the procedure.
Review Design and Search Strategy
We conducted a systematic review according to a prespecified protocol, which was registered on the PROSPERO database of systematic reviews. The protocol is accessible at: (http:// www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CR D42012002816). Ethics committee approval was not required because no new data were collected as part of this review. We included randomized controlled trials, which compared vitamin D or analogues with placebo, with a minimum exposure period of 4 weeks. The following databases were searched from inception to end of December 2016: Medline, EMBASE, CINAHL, ClinicalTrials.gov, and the Cochrane central register of controlled trials. Gray literature was sought using Google, and references of included studies were hand-searched for further candidate trials. Only trials where a full published trial report was available were included; trials published in abstract form only were excluded.
Trial Selection
Trials with changes in the following vascular markers were included: brachial artery flow-mediated dilatation; reactive hyperemia index measures using finger plethysmography;
Clinical Perspective
What Is New?
• This is the first individual participant data meta-analysis examining the effect of vitamin D analogues on markers of vascular function that are surrogates for cardiovascular events.
• No consistent effect was found at trial level or on analysis of individual participant-level data of supplementation on measures of endothelial function, arterial stiffness, or central blood pressure.
• No subgroup benefited consistently on analysis of individual participant data.
What Are the Clinical Implications?
• This analysis did not find convincing evidence of benefit from Vitamin D supplementation on a range of markers of vascular function.
pulse wave velocity (PWV) and pulse wave analysis; central aortic BP derived from peripheral artery tonometry; microvascular function measured using acetylcholine iontophoresis; and laser Doppler perfusion imaging. Studies with any baseline 25(OH)D level were eligible for inclusion. The following interventions were eligible for inclusion: vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol), calcitriol (1,25 hydroxyvitamin D3), 1-alpha-vitamin D, paricalcitol, and doxerocalciferol. Control groups receiving placebo were used and those receiving placebo plus cointervention were included, provided both arms of the study received the cointervention. A minimum of 4 weeks of therapy was necessary for inclusion to ensure sufficient time for vascular markers to change. Studies from both primary and secondary care or population settings were included; no restrictions were placed on sex or ethnicity. Studies recruiting participants less than 16 years old were not included, but in contrast to our previous review, 5 we did include studies of participants on renal replacement therapy (hemodialysis or peritoneal dialysis) given their very high cardiovascular risk and the current interest in using vitamin D supplementation therapy in this group. 
Data Extraction

IPD Collection
Lead authors for each included trial were contacted and invited to contribute individual-level participant data. Data were anonymized and transferred using a standard template before cleaning and incorporation in the final data set. Individual-level participant data were sought for age, sex, body mass index, baseline and follow-up 25(OH)D level, baseline medication use including ACE inhibitors and angiotensin receptor blockers, baseline estimated glomerular filtration rate (eGFR), total cholesterol, serum calcium and parathyroid hormone (PTH), presence of diabetes mellitus and previous vascular events, baseline and follow up BP and cholesterol, and baseline and follow-up measures of vascular function.
Risk of Bias Assessment
Risk of bias was evaluated by 2 authors independently, with discrepancies resolved by consensus. We assessed each included study for risk for bias using the following fields from a risk of bias checklist 9 : quality of random allocation concealment, intention-to-treat analysis, blinding of outcome assessors, treatment and control group comparability, clear definition of inclusion and exclusion criteria, participant blinding to allocation, and description of withdrawals and dropouts. Funnel plots were generated and inspected for evidence of publication bias, supplemented by Egger's test for funnel plot asymmetry.
Statistical Analysis
Meta-analysis at the trial level was performed using RevMan 5.3 software (Cochrane Collaboration). For all analyses, random-effects and fixed-effects meta-analyses using a weighted least-squares approach were performed. was undertaken for FMD, PWV, and augmentation index outcomes, regressing treatment effect on daily dose equivalent (for trials using vitamin D3) and trial duration in months. Metaregression was not used for other outcomes because there were too few to produce reliable results. Metaregression was undertaken using Comprehensive Meta Analysis tools software (version 3; Biostat, Englewood, NJ). A 2-stage analysis was used for IPD. 10 For each trial, or subgroup within each trial, mean outcome values at follow-up in each group were calculated and adjusted for baseline outcome values using ANCOVA (SPSS version 24; IBM, Armonk, NY). These values were then combined using RevMan software as described above. For those trials using more than 1 type or dose of vitamin D, the vitamin D arms were analyzed as a single arm. The following prespecified subgroup analyses were performed: diabetes mellitus versus no diabetes mellitus; baseline systolic BP of no greater than 140 mm Hg versus greater than 140 mm Hg; diastolic BP of no greater 
Results
A total of 31 trials, involving 2751 participants, were eligible for inclusion in the review. Of these, 29 trials (2641 participants) had data suitable for inclusion in the trial-level meta-analyses; IPD were obtained from 24 trials (2051 participants). The PRISMA flowchart is shown in Figure. One study that did not include data in the published article suitable for trial-level meta-analysis 36 provided IPD data and was included in the IPD analyses. Study size ranged from 24 to 305 participants; vitamin D3 was the most common intervention, being used in 23 of 31 (74%) of trials. The daily dose equivalent given in trials of vitamin D3 ranged from 900 to 5000 IU, and the duration of administration ranged from 4 weeks to 12 months. Paricalcitol was the only activated vitamin D analogue used in studies included in this review. Table 1 shows which vascular outcomes were measured in each included trial, and baseline trial characteristics are shown in Table 2 . assessors (29 of 31). Groups were comparable at baseline in 27 of 31 trials, dropouts were clearly described in 27 of 31 trials, but analysis was clearly by intention to treat in only 16 of 31 trials. A full description of the quality assessment for each trial is shown in Table 3 . Funnel plots showed no asymmetry for any of the vascular outcomes; Egger's test was calculated only for those outcomes with at least 10 trials to ensure reliability; this was nonsignificant for FMD (P=0.18), AIx (P=0.32), and PVW (P=0.70). Table 4 . Fixed-effects analyses showed similar point estimates, but narrower CIs, leading to a significant treatment effect for all vitamin D analogues on FMD (mean Table 5 . No association between these factors and treatment effect for PWV or AIx was found, but higher dose and shorter trial length were associated with a slightly greater treatment effect for FMD.
Risk of Bias Assessment
Trial-Level Data
Individual Participant Data
Similarly, meta-analysis of IPD showed no significant treatment effect on any of the vascular outcomes studied; no effect was evident when PWV analyses were confined to studies using carotid-femoral PWV. The main results for IPD analysis are shown in Table 6 . For most analyses, heterogeneity as shown by the I 2 statistic was low to moderate.
Prespecified subgroup analysis of IPD data for each vascular outcome (Tables 7 through 13 greater rise in aortic BP than those without diabetes mellitus. For outcomes in both trial-level and IPD analysis that were performed using SMD, standardizing SDs are given in Table 14 to facilitate interpretation at the individual trial level.
Discussion
The present meta-analysis found little evidence to support the hypothesis that supplementation of vitamin D or use of vitamin D analogues can improve markers of cardiovascular health. Our results were broadly consistent across a range of vascular markers and interventions, and subgroup analyses using IPD did not identify a subgroup that was more likely to benefit from treatment-this remained true even for those participants with the lowest 25(OH)D levels, with high baseline BP, and with higher baseline PTH levels. Randomeffects and fixed-effects analyses gave very similar results in the majority of analyses. Our results are consistent with our previous work that failed to find a beneficial effect of vitamin D therapy on BP 5 and are also in accord with 2 recent, smaller meta-analyses examining arterial stiffness and endothelial function. 42, 43 One further recent meta-analysis, examining only FMD, showed a slightly greater benefit (treatment effect of vitamin D was 1.27% for FMD), 44 perhaps attributable to differences in both study selection and the data used; our analysis had the benefit of access to IPD, which allowed us to verify the accuracy of published data and data used in previous meta-analyses. The results are also consistent with recent data suggesting no effect of vitamin D supplementation on plasma N-terminal pro-B-type natriuretic peptide levels or echocardiographic indices in older people after 12 months of therapy. Despite the large number of participants included in this analysis, it is not possible to completely refute the possibility that vitamin D or its analogues could still have a modest benefit on vascular health. The markers measured in studies included in this meta-analysis are subject to changes attributed to differences in environment, diet, smoking, medications, and operator skill; such factors require careful use of protocols to standardize measurement and reduce variability. 46, 47 The upper limit of the 95% CIs in our analyses encompasses a 1% improvement in FMD, a 1% improvement in AIx, a 0.3-m/s improvement in PWV, and a 5.6 mm Hg improvement in aortic systolic BP. A 5 mm Hg reduction in aortic systolic BP would be consistent with significant clinical benefit, and a 1% improvement in FMD would be consistent with an 8% to 13% reduction in cardiovascular event rates. 48, 49 A trial published too recently to be included in this systematic review suggested a large improvement in FMD in participants with nondialyzed CKD, 50 and it therefore remains possible that individuals with nondialyzed CKD, particularly with baseline low 25(OH)D levels, might benefit, although results from trials enrolling nondialyzed CKD participants that we included in this review showed improvement in FMD in only 1 of 3 trials. 11, 31, 34 Similarly, a recently published substudy using monthly high-dose vitamin D3 showed an improvement in aortic BP and arterial stiffness measures in those with baseline 25(OH)D levels <50 nmol/L; effect sizes were consistent with our IPD analysis findings for this subgroup. No significant improvements were observed in the overall trial group, however.
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Pooled observational data show that a log e difference in PWV (%2.7 m/s) corresponds to a 35% to 45% increase in the risk of a cardiovascular event. A 0.3-m/s improvement in PWV is therefore unlikely to be associated with a clinically important reduction in cardiovascular events. 52 Furthermore, it is still possible that agents such as paricalcitol might provide a greater magnitude of benefit to selected markers such as FMD. Paricalcitol is an active analogue of vitamin D (ie, it does not require further hydroxylation before binding to and activating the vitamin D receptor), and it is possible that this pharmacological difference from vitamin D2 or D3 might account for the observed result. It is, however, more likely that this result is attributed to the play of chance given the large number of comparisons contained in our analysis. A modest improvement in microvascular function with vitamin D was noted in the trial-level analysis, although this was of smaller magnitude in the IPD analyses and did not reach significance. The clinical significance of such an improvement in microvascular function is less clear than for changes in macrovascular markers, given that there are few long-term prognostic studies evaluating microvascular markers. Differences in the physiological control of small and large blood vessels, particularly the role of local metabolic factors in determining microvascular tone, may underpin the difference in response to vitamin D observed here. A number of limitations of our analysis require discussion. Despite the large number of participants, power for subgroup analyses was limited by the available data; most trials measured only 1 or 2 vascular outcomes, and some baseline variables were not collected in all trials. Caution is warranted in overinterpreting the results of positive associations in the IPD subgroup analyses; the large number of comparisons poses a risk of type I statistical error. Conversely, our decision to combine results from active treatment arms in trials with more than 1 active treatment arm risks diluting the apparent size of any treatment effect, although the impact of this is likely to be minimal given the small number of trials with more than 1 active treatment arm. For some outcomes, heterogeneity of measurement techniques required use of SMDs. Use of SMD limits the clinical utility of the results, and the heterogeneity of measurements means that translating SMD results to clinically meaningful values is challenging. However, use of SMD does at least allow some inferences about possible effect direction and magnitude to be obtained. Despite an extensive series of hypothesis-driven subgroup analyses and metaregressions to examine potential causes for heterogeneity, we were unable to identify subgroups of patients more likely to benefit from intervention, and heterogeneity in our IPD subgroup analyses remained high. Some of this heterogeneity may be attributable to the small number of trials in each analysis, but other, unmeasured sources of real difference between trials may still exist.
Although the risk of bias in most trials was low, only half of the included trials analyzed data by intention to treat, and the inclusion of trials with non-intention-to-treat analyses will tend 54 doses at the upper end of the range included in this analysis are required to reach this level. 40, 55, 56 Metaregression of vitamin D dose versus treatment effect suggested that higher doses of vitamin D were associated with a slightly greater treatment effect for FMD, but not for PWV or AIx. We found no evidence that daily dosing was more efficacious than intermittent dosing, despite previous work that has suggested that daily dosing provides more-consistent tissue exposure to the parent compound, facilitating uptake and autocrine activation, 57 and evidence that daily dosing may be more efficacious in some conditions (eg, respiratory disease). 58 Our results are consistent with our previous analysis that did not find a difference between daily and intermittent dosing on BP. 5 A final explanation that requires consideration is that the duration of therapy in most trials may simply have been too short to produce biological effects-particularly those trials intervening for only a few weeks. This explanation is plausible for outcomes such as arterial stiffness if biological effects are mediated by changes in vascular calcification, but seems less so for outcomes such as FMD and reactive hyperemia index, where other interventions are known to alter these parameters within days or weeks. Further evidence against this hypothesis is provided by the metaregression results, which suggest that longer trial duration was associated with a smaller treatment effect for FMD.
The results of these analyses add to the growing body of evidence suggesting that vitamin D supplementation may not have any beneficial effects on cardiovascular health. The lack of effect on vitamin D supplementation on BP in most studies to date 5, 53 and the lack of effect on vascular markers observed in the current analysis suggests that associations between 25(OH)D levels and cardiovascular events observed in observational studies may not be causal. Not all observational studies have been prospective in nature, and the degree of adjustment for confounders has been variable. There are several reasons why assumptions about causality may be incorrect, including reverse causality (where overt or preclinical illness leads to lower 25(OH)D levels through mechanisms such as immobility, obesity, or inflammation 59, 60 ), and confounding by shared risk factors for both cardiovascular disease and low 25(OH)D levels; obesity, inactivity, smoking, and advanced age are all known to be associated with lower 25(OH)D levels, and such confounding is notoriously difficult to fully adjust for. Existing evidence from meta-analyses of vascular events in osteoporosis trials using vitamin D does not support an effect of vitamin D in lowering cardiovascular event rates, 1, 7 with the possible exception of heart failure, and the first of a new wave of large, population-based vitamin D trials has recently reported, again showing no effect of vitamin D supplementation on cardiovascular event rates. 8 Randomized trials of relatively short duration cannot exclude a benefit of vitamin D supplementation over the span of a lifetime; observational designs including Mendelian randomization studies 61 may still be the only way to shed light on very long exposures to vitamin D, although even these designs are subject to bias and confounding. A number of other large vitamin D trials are due to report over the next 3 to 4 years, 62 and most of these include cardiovascular events as key outcomes-outcomes which our analysis did not focus on. Existing evidence does not support the use of vitamin D to reduce cardiovascular risk, and the results of our analysis do not suggest a specific target group that is particularly likely to benefit from vitamin D supplementation, although we found no evidence of a deleterious effect on cardiovascular function. The relative lack of representation of some groups, particularly nonwhite groups, tempers the generalizability of this conclusion. In the absence of a subgroup with clear benefit, and with large trial reports expected soon, further small-scale trials examining surrogate vascular end points are unlikely to advance this field of research significantly. 
